Lantheus will continue to provide products for ultrasound diagnostic imaging procedures. Source: University College of London

The former Bristol-Myers Squibb (BMS) Medical Imaging, which provided medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, has become Lantheus Medical Imaging.

The new corporate identity was created through the acquisition of the BMS unit by Avista Capital Partners in January for $525 million.

The North Billerica, Mass.-based company will continue to provide medical imaging products for nuclear and ultrasound cardiovascular diagnostic imaging procedures, including Cardiolite, Definity and TechneLite, said Avista.
 
Lantheus also announced the appointment of Don Kiepert as president and CEO. Prior to joining Lantheus, Kiepert was the founder and former chairman, CEO and president of Point Therapeutics since 1996.

In conjunction with the launch of the business, Lantheus also announced key members of its management team. Phillip Lockwood was appointed vice president, human resources, having previously served as vice president, human resources at Indevus Pharmaceuticals.

Additionally, the company name Michael Duffy, who was formerly senior vice president and general counsel at Point Therapeutics, as vice president and general counsel.